IRG Research Introduces the First Source of Weekly Oncology Prescription Data for Investors

Share Article

IRG Research, the independent equity research firm and securities broker-dealer, through its healthcare alliance partner MDRx Financial, today introduced a proprietary weekly oncology prescription data source -- the largest available to the financial community -- to help institutional investors make better decisions in the biotechnology sector.

IRG Research, the independent equity research firm and securities broker-dealer, through its healthcare alliance partner MDRx Financial, today introduced a proprietary weekly oncology prescription data source -- the largest available to the financial community -- to help institutional investors make better decisions in the biotechnology sector.

The IRG/MDRx prescription data source expands on IRG/MDRx's ability to give institutional investors a unique source of healthcare intelligence through proprietary retail pharmacy, biotech and pharmacy prescription databases along with access to top doctors in America and a network of leading pharmacists and distributors.

The proprietary IRG/MDRx oncology data source tracks the prescriptions of more than 500 high-prescribing U.S. oncologists nationwide, representing approximately 5% of the $32 billion U.S. oncology market -- the first time this level of information has been available to investors.

"With the IRG/MDRx oncology data source, our institutional investor clients will now have an in-depth look at prescription trend changes weeks ahead of any other information source on the market," said Joseph C. Marino, managing director and chief operating officer of IRG Research.

"These oncology drugs are not sold in pharmacies, but are infused at the oncologist's practice. So for investors to know what's happening in hundreds of oncologists' offices on a weekly basis is a remarkable thing," said Keith Pride, partner and co-founder of MDRxFinancial.

The IRG/MDRx resource's fully-dynamic interface allows investors to analyze drugs by prescription, by price, by company, and even by the diseases each drug treats, said Pride.

About IRG Research

IRG Research is a registered broker-dealer created to provide institutional and hedge fund money managers with unbiased and differentiated equity research. IRG's top-tier industry analysts provide in-depth, action-oriented investment ideas without the conflicts created by investment banking, underwriting, and proprietary trading. Analysts concentrate on uncovered and under-covered stocks and have a small to mid-cap focus. Sector coverage includes Aerospace & Defense, Biotech, Communications Equipment; Communications Services & Infrastructure; Energy; Financial Services; Leisure, Graphics & Imaging; Satellite, Cable & Broadcasting; Specialty Retail - Softlines; Specialty Retail - Hardlines and Technology. IRG also provides clients direct and unfiltered access to key industry participants, management teams, and thought leaders through its IRG Institutional Marketing Group. IRG Research is a wholly owned subsidiary of TheStreet.com (NASDAQ: TSCM). Additional information about IRG Research can be found at http://www.irgresearch.com.

Statements contained in this news release not related to historical facts may be deemed forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties (described in the Company's SEC filings), which could cause actual results to differ.

About MDRxFinancial

MDRxFinancial was founded in 2002 to provide independent research on the healthcare industry. MDRxFinancial combines unique sources of data and industry experts to deliver a comprehensive and dynamic view of the health care marketplace. In conjunction with its strategic partner, Castle Connolly Medical, MDRx has created a network of 5,000 top board-certified physician specialists in America, representing the finest medical centers and research hospitals. MDRx also has two proprietary prescription databases that will be available to IRG clients. The first is a retail prescription and pricing database from over 3,000 independent pharmacies and wholesalers across the US. This data is available days ahead of the other leading sources of pharmaceutical information used by the investment community. The second is an oncology product database that reflects 10% of total oncology drug-related sales in the US. MDRx's proprietary online pharmaceutical sales data engine provides fully dynamic views of any of the 40,000 prescription drugs sold in the US. In addition to the network and databases from MDRx, IRG expects to provide access to board-certified pharmacists for phone consultation and surveys. Additional information about MDRXFinancial can be found at http://www.mdrxfinancial.com.

Contacts:

Wendy Marx

Marx Communications

203-445-2850

wendy@marxcommunications.com

Tom Mariam

Marx Communications

914-939-4294

tom@marxcommunications.com

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Wendy Marx
Visit website